Mark Sullivan Email

Director Phage Technologies . Neoclone Biotechnology

,

Location

LinkedIn

Current Roles

Employees:
6
Revenue:
$930k
About
NeoClone produces high-quality monoclonal antibody products for the biotechnology and research markets. In addition to generating monoclonals through the traditional fusion technology NeoClone holds exclusive license to the ABL-MYC retroviral transformation system, a technique that produces monoclonal antibodies -- "NeoClone®"-brand or "NeoAb®" antibodies -- in an accelerated time and with cost savings. This allows NeoClone to provide custom antibodies faster and more cost effective.
Neoclone Biotechnology Address
1202 Ann Street
null, null
United States
Neoclone Biotechnology Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.